Article
18 Mar 2026
Multi-Year Insurance Audits Of Physical Therapy Practices: Documentation, Medical Necessity, And The Growing Use Of Extrapolation
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
18 Mar 2026
ERISA Class Action on Prescription Drug Benefits Gets Green Light — A Warning for Plan Sponsors
Article
13 Mar 2026
State Enforcement Against Pharmacy Benefit Managers Intensifies: Lessons From Louisiana And West Virginia
Article
13 Feb 2026
Oral Semaglutide And The GLP-1 Compounding Reckoning: From Regulatory Ambiguity To FDA Enforcement, DOJ Referrals, And Novo Nordisk's Case Against Hims & Hers
Article
28 Jan 2026
California's PBM Fiduciary Law Faces An ERISA Challenge – Why This Matters For Independent Pharmacies And Patients
Article
26 Jan 2026
A Pivotal Moment For Patients And Independent Pharmacies: Congress Acts On PBM Reform With Bipartisan Legislation
Article
22 Jan 2026
New Wave Of ERISA Class Action Lawsuits Name Brokers As Defendants
Article
14 Jan 2026
When Pass-Through Isn't Pass-Through: PBM GPOs And The Reengineering Of Rebates
Article
14 Jan 2026
National Pharmacy Benefit Manager Implements Direct-to-Consumer Model
Article
30 Dec 2025
Year-End And Early-Year PBM Network Enforcement: Why Pharmacies Must Stay Vigilant Right Now
Article
24 Dec 2025
OptumRx Follows Other PBMs' Playbooks: Therapeutic Class Caps Signal The Next Phase Of PBM Oversight
Article
19 Dec 2025
Compounded GLP-1 Advertising: What Compounders Need To Know NOW
Article
18 Dec 2025
PBMs As De Facto Regulators: A 2025 Recap Of PBM Audits And Their Growing Impact On Board Of Pharmacy Enforcement
Article
02 Dec 2025
Recent Updates Transforming Plan Sponsor Relationships With Pharmacy Benefit Managers
Article
01 Dec 2025
State PBM Oversight Has Been Growing But Enforcement Still Falls Short: Why Pharmacies Must Step Up
Article
19 Nov 2025
Cigna's Rebate-Free Model: What It Really Means For Plan Sponsors, Pharmacies And The Industry
Article
17 Oct 2025
The PBM Effect: Regulatory And Market Implications For Life Sciences Companies And Healthcare Providers
Article
10 Oct 2025
TrumpRx: What Pharmacies And Plan Sponsors Need To Know
Article
29 Sep 2025
AstraZeneca Doubles Down: Pharmacies Face Escalated Requests For Farxiga® Dispensing Records
Article
24 Sep 2025
Corresponding Responsibility: Why Pharmacies Must Take It Seriously — And How A Mock DEA Audit Can Protect Your Business
